As much as I like giving this guy crap for sounding like a robot, he has a couple of good points here:
LabMan05:47 AM$KZIA The pAX WBRT presentation was elevated into the core program of the SNO two day conference. It was not done so, because of ambiguity, as to efficacy of the combination treatment. That can be assured. Wording used in the early post, to describe the pAX, GBM AGILE results, would suggest some direct or indirect stakeholder involvement and was inappropriate. PI3K/mTOR pathway deregulation is known to correlate with radio resistance in brain mets. In the study by Dr Yang, early stage non invasive metabolic changes would be detected by spectroscopy. Lactate and phosphocholine levels are measurable within 7 days of combination administration, as such can serve to biomark PI3K inhibition to RT. Since PI3K inhibition does not only affect the metastatic cells but also re-educates the metastasis-promoting macrophages/microglia, PI3K inhibition holds considerable promise in the treatment of brain metastasis and the respective microenvironment. We have seen positive early stage signs of that,
- Forums
- ASX - By Stock
- KZA
- KZA Media Thread
KZA Media Thread, page-2016
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online